French vet-med maker Virbac has named Frédéric Jodogne as Corporate Industrial Operations director in early April. He is in charge of implementing, organizing and leading supply chain and industrial strategies of the Group.
Jan Holmgren, developer of the first effective oral cholera vaccine, has been awarded the 2017 Sabin Gold Medal for his pioneering contributions to oral vaccine research and mucosal immunology, and his leadership in the discovery of the world’s first effective oral cholera vaccine.
Pharmalink AB has hired Renee Aguiar-Lucander as Chief Executive Officer. She will lead the expansion and strategic development of the Swedish specialty pharmaceutical company following the clinical success of its orphan drug Nefecon.
Cambridge-based specialist ion channel CRO and drug discovery company Metrion Biosciences Ltd has named James Beaumont Head of Business Development. He joins from NZP-Dextra, where he held the post of Development Director.
Gyros Protein Technologies has appointed Mark Vossenaar as Vice President, European Sales.
Paris-based biopharma GenSight Biologics SA named Mohamed Genead as Chief Medical Officer in early May. Most recently, Genead was Vice President & Global Therapeutic Area Head for Ophthalmology/Retina Gene Therapy at Biogen.
Antibody developer Kymab Ltd has instated Sonia Quaratino as its first Chief Medical Officer. She will manage the clinical development of the Group’s expanding therapeutic antibody portfolio.
Biopharmaceutical company Oryzon Genomics has named Roger Bullock its Chief Medical Officer. He will be responsible for executing the clinical development plan of the epigenetic drugs developed by the company.
London-based immunotherapy developer GammaDelta Therapeutics has hired Paolo Paoletti as Chief Executive Officer. Paoletti was formerly the first appointed President of GSK Oncology, where he was responsible for the overall oncology business.
Modus Therapeutics AB, a Karolinska Development portfolio company developing treatments for sickle cell disease, has appointed Ellen K. Donnelly as CEO. Donnelly joins from Pfizer, Inc, where she most recently was responsible for Clinical Operations for the Neuroscience and Pain therapeutic area.